Core Insights - The company announced positive results from the TranStar102 clinical trial, which evaluated osemitamab in combination with nivolumab and CAPOX for the treatment of gastric or gastroesophageal junction adenocarcinoma [1][2] - The updated efficacy analysis showed a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among patients with high CLDN18.2 expression [1] - The results indicate that the treatment benefits of osemitamab are consistent across different PD-L1 expression subgroups, suggesting its potential effectiveness for a broader patient population [2] Efficacy Analysis - The study involved 26 patients with CLDN18.2 expression ≥40% and PD-L1 CPS known, with a median follow-up of 25.8 months [1] - The median duration of response (mDoR) was reported at 18 months, highlighting the durability of the treatment response [1] - The analysis confirmed that higher CLDN18.2 expression correlates with better PFS outcomes, regardless of PD-L1 expression levels [1] Safety Profile - The safety characteristics of the treatment were consistent with previously reported data from the ASCO 2025 conference [2] - The combination therapy demonstrated good safety and tolerability, reinforcing its potential as a first-line treatment option for advanced gastric or gastroesophageal junction adenocarcinoma [2] - The clinical benefits observed in the study are expected to provide significant improvements for patients in need of more effective treatment options [2]